None ...

AstraZeneca AZN announced that the FDA has accepted a regulatory filing seeking to expand the use of its blockbuster rare ...

If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market.

AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.

AstraZeneca’s SOUNDTRACK-F1 study aims to improve on related risks seen with chemotherapy-including treatments in follicular ...

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss ...

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout the research process.

View AstraZeneca PLC AZN stock quote prices, financial information, real-time forecasts, and company news from CNN.

The positive results come from the Phase 2 VISTA clinical trial, which evaluated elecoglipron in adults with obesity or ...

By Maggie Fick LONDON, June 8 (Reuters) - AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 weeks in a mid-stage trial of its experimental obesity pill, as the ...

LONDON (AP) — The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator. In an update on the European ...

AstraZeneca’s Truqap (capivasertib) gained FDA approval, combined with abiraterone and prednisone, for treatment of certain ...